What Is DSIP? Benefits, Research & Safety
A neuropeptide originally isolated for its sleep-inducing properties, now researched for stress protection, pain modulation, and metabolic effects.
UK summary: Not a licensed UK medicine. Endogenous peptide investigated for sleep, pain, and stress-protection in older Russian / Eastern European studies; modern human evidence is sparse.
Quick Facts
Overview
DSIP — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
Not a licensed UK medicine. Endogenous peptide investigated for sleep, pain, and stress-protection in older Russian / Eastern European studies; modern human evidence is sparse.
02Human evidence grade
03Preclinical evidence grade
04Regulatory status
- UK: Not licensed for human use. Research compound only.
- EU: Not widely approved; limited clinical use in some countries historically.
- Notes: DSIP has been used clinically in some European countries but is not widely approved. Regulatory status varies. Not available through standard medical channels in the UK.
05Approved medical uses
None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)
06Unapproved / promotional claims
- Restores natural delta-wave sleep without side effects.
- Effective treatment for chronic insomnia.
- Non-addictive alternative to Z-drugs and benzodiazepines.
- Improves stress resilience and HPA-axis function.
07Common internet claims
- Marketed as the original sleep peptide for biohackers.
- Sold by online retailers as a research-only injection or nasal spray.
- Recommended in longevity stacks for sleep-architecture optimisation.
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Cures insomnia naturally” | D | Limited | High | Older studies suggest sleep effects; modern controlled human evidence is limited. Insomnia should be assessed by a clinician. |
| “Safe non-addictive sleep aid” | E | No | High | Long-term human safety is not established. |
09Safety uncertainty score
Limited human safety data; meaningful uncertainty about rare or long-term effects.
10Known adverse signals
- Limited systematic safety data.
- Injection-site reactions.
- Unknown chronic effects on neuroendocrine signalling.
- Interactions with sedatives, alcohol, and SSRIs unstudied.
11Drug-interaction uncertainty
Interaction picture sparse; meaningful uncertainty when combined with other medicines.
12Anti-doping status
13UK legal position
Not licensed for human use. Research compound only.
14EU legal position
Not widely approved; limited clinical use in some countries historically.
15What this page cannot tell you
- Whether a UK-purchased vial contains DSIP at the labelled concentration.
- How chronic use affects natural sleep-cycle regulation.
- Whether it adds risk in combination with prescribed sleep medications.
- What the effective dose is in humans — no licensed reference exists.
16Last reviewed
17Citation quality score
18Research gaps
- Most positive data comes from 1970s-1980s Eastern European studies with limited modern replication.
- No registered Western Phase 3 trials.
- Mechanism of action is not fully characterised even after 50 years.
- Long-term safety unstudied.
19Safer alternatives / established care pathways
- CBT for insomnia (CBT-I) via NHS Talking Therapies — NICE first-line.
- Sleep hygiene fundamentals (caffeine, alcohol, light, schedule).
- Licensed melatonin (Circadin) for over-55s with primary insomnia.
- GP review for sleep apnoea, depression, or other underlying causes.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is DSIP a licensed UK medicine?
- What licensed UK sleep treatments should be considered first?
- Should my insomnia be investigated for an underlying cause?
Discovery & History
Mechanism of Action
Researched Benefits
Based on preclinical and clinical research findings:
- 1Potential improvement in sleep quality and delta wave sleep
- 2Stress-protective effects in some research
- 3Pain modulation and analgesic properties
- 4Possible benefits in substance dependence treatment
- 5Hormonal regulation effects
- 6Antioxidant and neuroprotective properties
Claim vs Evidence
How popular claims about DSIP stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Cures insomnia naturally” | D | Limited | High | Older studies suggest sleep effects; modern controlled human evidence is limited. Insomnia should be assessed by a clinician. |
| “Safe non-addictive sleep aid” | E | No | High | Long-term human safety is not established. |
Theoretical Dosing & Protocols
| Theoretical Dosage | 100-300 mcg per administration (based on various research protocols) |
| Frequency | Once daily, typically in the evening |
| Duration | Variable; typically several weeks in clinical studies |
| Notes | Protocols vary significantly across studies. DSIP is not approved in the UK/EU. Any use should be approached with caution and ideally under medical supervision. |
Administration Routes
Routes studied in research settings (educational only):
- Subcutaneous injection
- Intravenous injection (clinical settings)
- Intranasal (some formulations)
| Half-Life | Stability |
|---|---|
| Relatively short; approximately 15-25 minutes in circulation | Lyophilised powder should be stored refrigerated or frozen |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Generally well-tolerated in studies
- Headache in some individuals
- Transient nausea
- Injection site reactions
Rare Risks & Concerns
- Limited comprehensive safety data
- Potential effects on hormone systems with chronic use
- Long-term effects unknown
Contraindications
- Pregnancy and breastfeeding
- Severe depression or psychiatric disorders
- Hormone-sensitive conditions
- Children and adolescents
UK & EU Regulatory Context
🇬🇧 United Kingdom
Not licensed for human use. Research compound only.
🇪🇺 European Union
Not widely approved; limited clinical use in some countries historically.
Clinical Studies Summary
Delta Sleep-Inducing Peptide: Clinical Studies and Research Review
Various clinical investigations into DSIP's effects on sleep, pain, and other conditions.
Looking for DSIP?
Source research-grade DSIP from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about DSIP
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is DSIP a licensed UK medicine?
- What licensed UK sleep treatments should be considered first?
- Should my insomnia be investigated for an underlying cause?
UK regulatory & safety context
Related Research Guides
Related Peptides
Selank
A synthetic peptide based on tuftsin, developed in Russia for anxiolytic and nootropic properties, approved there for anxiety and neurasthenia.
Learn moreSemax
A synthetic peptide based on ACTH, developed in Russia as a nootropic and neuroprotectant, approved there for cognitive disorders and stroke.
Learn moreKisspeptin-10
A decapeptide hormone critical for initiating puberty and regulating reproductive hormone release, with emerging research applications.
Learn more